COVID-19 - November 16, 2020
Baricitinib reduced the mortality in COVID-19 patients shows new research
The rheumatoid arthritis drug baricitinib can block viral entry and reduce mortality in patients with moderate to severe COVID-19, according to new research. “We are pleased to report a 71 percent reduction in mortality for the group receiving baricitinib in addition to standard care,” says Volker Lauschke, corresponding author and associate professor of personalized medicine and drug […]
COVID-19 - November 15, 2020
Five Nordic research projects awarded grants for COVID-19 research
The new projects will take advantage of the Nordic countries’ unique health data to advance the knowledge base about COVID-19 and have been awarded roughly NOK 53 million in funding. NordForsk, an organisation under the Nordic Council of Ministers, is providing funding for the COVID-19 research projects together with a number of national research agencies […]
COVID-19 - November 9, 2020
Exclusive interview: Mikael Dolsten, Chief Scientific Officer, Pfizer
The days are busy for Sweden’s Mikael Dolsten. As head of Pfizer’s R&D he is at the scientific forefront of the fight against the COVID-19 pandemic. Scientists and researchers across the globe are racing as never before to find treatments and a vaccine for the new coronavirus that has killed more than half a million […]
COVID-19 - November 9, 2020
Promising results from Pfizer and BioNTech’s vaccine trial
Pfizer and BioNTech have announced that their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection, based on the first interim efficacy analysis conducted on November 8, 2020 by an external, independent Data Monitoring Committee (DMC) from the Phase 3 clinical study. The […]
COVID-19 - November 4, 2020
Lund-based research organizations form consortium
A consortium of private and public organisations announces a collaboration that aims to assemble and utilize a platform for rapid response to the current SARS-CoV-2 pandemic as well as future threats. The consortium, LundaGUARD, consists of partners with complementary capabilities and expertise in structure-based drug discovery. It includes the European Spallation Source (ESS), the The Lund […]
COVID-19 - October 26, 2020
FDA authorises restart of the AZD1222 vaccine US Phase III trial
Clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed across the world with regulators in the US, UK, Brazil, South Africa and Japan confirming that it was safe to do so. The Food and Drug Administration (FDA) authorised the restart in the US, following the resumption of trials in other countries in recent […]
